pancreastatin-52 and Bone-Neoplasms

In this study, we look at the clinical features associated with bone metastasis in patients with well-to-moderately differentiated neuroendocrine tumors (NETs), specifically primary tumor characteristics, complications, elevated hormone levels, and survival.. A retrospective study at the Ohio State University was performed on patients diagnosed with well-to-moderately differentiated NETs from 2000 to 2010 who were found to have bone metastases. A control group of patients with metastatic NETs without bone metastases was matched with regard to demographic and clinical data.. Of 341 patients with well-to-moderately differentiated NETs, 40 patients were found with bone metastases within the 10-year study period. Patients with bone metastases had shorter survival (median, 52 months) compared to the control group (median, 98 months; P = 0.024). Of 26 patients with bone metastases who died, 6 (23%) patients had a cause of death related to their bone metastatic disease. There were 8 patients with spinal cord compression, and 6 with pathologic fractures.. Our study suggests that patients with well-to-moderately differentiated NETs metastatic to bone have larger tumors, more frequently elevated pancreastatin, and shorter survival than patients without bone metastases, with complications of bone metastases significantly contributing to mortality and morbidity.

Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Cause of Death; Cell Differentiation; Databases, Factual; Female; Fractures, Spontaneous; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Ohio; Pancreatic Hormones; Prognosis; Retrospective Studies; Risk Factors; Spinal Cord Compression; Time Factors; Tumor Burden